Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
P49407
UPID:
ARRB1_HUMAN
Alternative names:
Arrestin beta-1; Non-visual arrestin-2
Alternative UPACC:
P49407; B6V9G8; O75625; O75630; Q2PP20; Q9BTK8
Background:
Beta-arrestin-1, also known as Arrestin beta-1 or Non-visual arrestin-2, plays a pivotal role in G-protein coupled receptor (GPCR) signaling. It mediates receptor desensitization and resensitization, crucial for cellular response modulation. Beta-arrestin-1 facilitates receptor internalization, serving as an adapter for clathrin-coated pits, and influences receptor trafficking and signaling, including MAPK pathways activation.
Therapeutic significance:
Understanding the role of Beta-arrestin-1 could open doors to potential therapeutic strategies. Its involvement in GPCR signaling and receptor trafficking highlights its potential as a target in diseases where these pathways are dysregulated.